 |
Alteogen Headquarters. (Photo: Alteogen) |
[Alpha Biz= Ellie Kim] The U.S. Patent Trial and Appeal Board (PTAB) has invalidated key patent claims held by Halozyme Therapeutics related to its MDASE technology, in a decision seen as favorable to Alteogen.
According to the PTAB’s final written decision released on May 12 (local time), all challenged claims (1–4, 8–21) of U.S. Patent No. 11,952,600 were deemed unpatentable. The patent pertains to modified PH20 hyaluronidase proteins associated with MDASE.
The PTAB concluded that the patent failed to meet disclosure requirements, noting that while the claims were broadly defined, the specification did not sufficiently describe the full scope of the claimed invention. As a result, the board found that a person skilled in the field would not be able to reproduce the entire claimed range based on the patent description, thereby also failing the enablement requirement.
Halozyme had sought to use the patent to broadly cover a wide range of active PH20 variants. However, the PTAB determined that the claims were not adequately supported by the underlying disclosure, leading to the invalidation.
Alphabiz Ellie Kim 인턴기자(press@alphabiz.co.kr)
